Mydocalm (Tolperisone Hydrochloride)

Tolperisone hydrochloride, the active ingredient in Mydocalm, is a centrally acting skeletal muscle relaxant presented as an oral tablet for oral use. It is employed to reduce muscle tone and alleviate spasticity in patients with muscle‑related disorders.

GNH USA supplies Mydocalm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global distribution. With a focus on consistent product integrity, GNH USA supports healthcare providers in delivering effective muscle‑relaxant therapy across diverse markets.

Mydocalm (tolperisone hydrochloride) acts on the central nervous system to reduce abnormal muscle tone in several conditions.

- Muscle spasm: alleviates involuntary muscle contractions and associated discomfort. - Skeletal muscle pain: reduces pain related to muscle strain or overuse. - Spasticity associated with neurological disorders: diminishes heightened muscle tone in conditions such as multiple sclerosis or post‑stroke syndrome.

Tolperisone hydrochloride may be associated with a range of adverse reactions, varying from mild and transient to serious and potentially life‑threatening.

Common Side Effects: - Dizziness: a feeling of light‑headedness or unsteadiness that may affect balance. - Nausea: mild to moderate stomach upset, sometimes accompanied by a urge to vomit. - Headache: transient cranial discomfort ranging from mild pressure to throbbing pain.

Serious or Rare Side Effects: - Hypotension: a marked reduction in blood pressure that can cause fainting or dizziness. - Hepatotoxicity: signs of liver injury such as jaundice, elevated liver enzymes, or abdominal pain. - Anaphylaxis: an acute allergic reaction presenting with breathing difficulty, swelling, hives, and possible shock.

When prescribing Mydocalm, clinicians should consider several precautionary measures to ensure patient safety.

- Renal impairment: assess kidney function and adjust therapy if necessary. - Hepatic impairment: monitor liver enzymes and use with caution in liver disease. - Elderly patients: start with lower doses and observe for increased sensitivity. - Concomitant CNS depressants: evaluate risk of additive sedation or dizziness. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mydocalm may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other centrally acting muscle relaxants: combined effect may cause excessive muscle weakness. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypotension or serotonin syndrome. - Strong CYP450 inhibitors: may increase tolperisone plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure‑lowering effect. - Antidiabetic medications: possible alteration of glucose control. - Alcohol: may enhance central nervous system depression.